Docking and QSAR studies of aryl-valproic acid derivatives to identify anti-proliferative agents targeting the HDAC8.

Martínez-Pacheco, Heidy; Ramírez-Galicia, Guillermo; Vergara-Arias, Midalia; Gertsch, Jürg; Fragoso-Vázquez, Jonathan Manuel; Méndez-Luna, David; Abujamra, A L; Cristina, Cabrera-Pérez Laura; Cecilia, Rosales-Hernández Martha; Mendoza-Lujambio, I; Correa-Basurto, José (2017). Docking and QSAR studies of aryl-valproic acid derivatives to identify anti-proliferative agents targeting the HDAC8. Anti-cancer agents in medicinal chemistry, 17(7), pp. 927-940. Bentham Science Publishers

[img] Text
Docking and QSAR Studies of Abstract.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (210kB) | Request a copy
[img] Text
Docking and QSAR Studies of.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (4MB) | Request a copy

Histone deacetylase 8 (HDAC8) is a plausible target for the development of novel anticancer drugs using a metal-chelating group and hydrophobic moieties as pharmacophores. It is known that valproic acid (administered as its salt, sodium valproate; VPANa+) is an HDAC8 inhibitor characterized by its hydrophobic chains. Nevertheless, VPA is hepatotoxic and VPA analogues might be explored for less hepatotoxic antiproliferative compounds. In this work, docking and QSAR studies of 500 aryl-VPA derivatives as possible HDAC8 inhibitors were performed in order to explore and select potential anti-proliferative compounds. Docking results identified π-π hydrogen bonds as the most important noncovalent interactions between HDAC8 (PDB: 3F07) and the ligands tested, whereas Belm4 was the best QSAR descriptor and classified as a 2D-BCUT descriptor. Based on theoretical studies, compound DAVP042 was synthesized and evaluated in vitro for its anti-proliferative activities on several cancer cell lines (A549 - lung, MCF-7 - breast, HCT116 - colon and U937 - lymphoid tissue) in comparison to VPA, as well as for its inhibitory activity on HDAC8 using in vitro models. DAVP042 demonstrated to have antiproliferative activity on all cancer cell lines employed, not only suggesting that this compound should be further studied, but also demonstrating that the methodology herein employed is appropriated to identify new therapeutic candidates.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Other Institutions > NCCR TransCure
04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Biochemistry and Molecular Medicine

UniBE Contributor:

Gertsch, Jürg

Subjects:

500 Science > 570 Life sciences; biology
600 Technology > 610 Medicine & health

ISSN:

1875-5992

Publisher:

Bentham Science Publishers

Language:

English

Submitter:

Barbara Järmann-Bangerter

Date Deposited:

28 Feb 2017 15:29

Last Modified:

10 Sep 2017 20:05

PubMed ID:

27774878

BORIS DOI:

10.7892/boris.94306

URI:

https://boris.unibe.ch/id/eprint/94306

Actions (login required)

Edit item Edit item
Provide Feedback